Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term immunotherapy. Found 18 abstracts

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr;123(7):1259-71.   PMCID: PMC5705038
Marty R, Kaabinejadian S, Rossell D, Slifker MJ, van de Haar J, Engin HB, de Prisco N, Ideker T, Hildebrand WH, Font-Burgada J, Carter H. MHC-I Genotype Restricts the Oncogenic Mutational Landscape. Cell. 2017 Nov 30;171(6):1272-1283 e15.   PMCID: PMC5711564
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MH, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017 Jul;28(7):1436-47.
Jochems C, Hodge JW, Fantini M, Fujii R, Morillon Ii YM, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget. 2016 Dec 27;7(52):86359-73.   PMCID: PMC5341330
Uzzo RG, Horwitz EM, Plimack ER. Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care. Future Oncol. 2016 Feb 17;12(7):887-91.
Zibelman M, Ghatalia P, Geynisman DM, Plimack ER. Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. Immunotherapy. 2016 Jun;8(7):785-98.
Zibelman M, Plimack ER. Systemic therapy for bladder cancer finally comes into a new age. Future Oncol. 2016 Oct;12(19):2227-42.   PMCID: PMC5066115
Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy. 2012 May;61(5):629-41.
Wang SZ, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunology Immunotherapy. 2012 Jan;61(1):49-61.   PMCID: PMC3517883
Boorjian SA, Zhu F, Herr HW. The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU international. 2010 Aug;106(3):357-61.   PMCID: *
Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L. Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference. Cancer . 2009 Jan;115(10):2247-51.   PMCID: PMC2892290
Boorjian SA, Berglund RK, Maschino AC, Savage CJ, Herr HW. Fibrin Clot Inhibitor Medication and Efficacy of Bacillus Calmette-Guerin for Bladder Urothelial Cancer. Journal of Urology. 2009 Oct;182(4):1306-11.
Ignatoff JA, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group. Urologic Oncology-Seminars and Original Investigations. 2009 Sep;27(5):496-501.   PMCID: PMC2743955
Halbert RJ, Figlin RA, Atkins MB, Bernal M, Hutson TE, Uzzo RG, Bukowski RM, Khan KD, Wood CG, Dubois RW, Peacock S, Apicella C, Andrews L, Tucker K, Bankier A, Daly MB, Hopper JL. Treatment of patients with metastatic renal cell cancer - A RAND appropriateness panel. A discrete choice experiment of preferences for genetic counselling among Jewish women seeking cancer genetics services. Cancer. 2006 Nov;95(10):1448-53.
Kaye SB, Eisenhauer EA, Hamilton TC. New non-cytotoxic approaches to ovarian cancer. Annals of Oncology. 1999 Jan;10:65-8.
Orlow SJ, Silvers WK, Zhou BK, Mintz B. Comparative decreases in tyrosinase, TRP-1, TRP-2, and Pmel 17/silver antigenic proteins from melanotic to amelanotic stages of syngeneic mouse cutaneous melanomas and metastases. Cancer Research. 1998 Apr;58(7):1521-3.
Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM, Adams GP. In-Vitro and in-Vivo Characterization of a Human Anti-C-Erbb-2 Single-Chain Fv Isolated from a Filamentous Phage Antibody Library. Immunotechnology. 1995 May;1(1):73-81.
Moutschen MP, Shan H, Giantonio BJ, Bookman MA. Precursor Ctl Specific for Retrovirus-Induced T-Lymphoma Are Found at High-Frequency in Unprimed Syngeneic Mice. Cellular Immunology. 1994 Feb;153(2):367-77.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term immunotherapy

immunotherapy expression transitional-cell carcinoma therapy carcinoma immune-response urinary-bladder methods clinical trials renal cell carcinoma Combined Modality Therapy Immunotherapy bladder cancer immunology cancer lymphoma immune checkpoint blockade cytolytic t-lymphocytes cell-lines androgen efficacy OVARIAN-CANCER cells human leukocyte antigen CONJOINT-ANALYSIS Fox Chase Cancer Center kidney cancer BREAST-CANCER cetuximab Toll-like receptor 4 agonist her-2 receptor Bladder genes Pfizer and Bristol-Myers Squibb and has received institutionally Novartis antigens Neoplasm Metastasis randomized trial Dendritic cell Ovarian cancer-Vaccine-Clinical trial-Consolidation therapy manuscript heavy instillation Head and Neck Neoplasms Monoclonal Antibodies neoplasm metastasis risk Neoadjuvant Therapy adverse effects repertoire organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those anti-cd20 monoclonal-antibody transgenic mice HEALTH-CARE signal neoadjuvant chemotherapy immunoediting TRIAL peptide INFORMATION cytolytic lymphocytes-t HIGH-DOSE THERAPY checkpoint blockade biomarkers cancer predisposition Immunologic Factors Ashkenazi tumor-associated antigen Superficial transitional cell carcinoma checkpoint inhibitors oncology-group BRCA2 MUTATIONS Urothelial carcinoma repair Adcc cancer susceptibility prediction FAMILIAL BREAST renal cancer AstraZeneca and Merck directed clinical trial support from Bristol-Myers Squibb phage antibody library cytotoxic T-lymphocyte associated protein 4 Targeted therapy reproductive factors adriamycin head and neck cancer toxicity Mycobacterium bovis murine leukemia BONE-MARROW AUTOTRANSPLANTS OUTCOMES lymphocytes prostate cancer hla-a2 phase-i Ctla-4 genetic therapy INTERLEUKIN-2 discrete choice experiment identification PLUS INTERFERON-ALPHA receptor agonists genitourinary cancer pathology system transplantation mortality BLOOD-CELL urothelial cell Clinical Trials as Topic metalloproteinase inhibitors human-breast Pd-1 breast cancer BRCA1 and BRCA2 resistance high affinity CD16 major histocompatibility complex angiogenesis response criteria antigen presentation etiology genetics neu Treatment Outcome gp100 clones in-situ vascular endothelial growth factor superficial bladder-cancer survival CARCINOMA disclosed No writing assistance was utilized in the production of this waterfall plots urothelial carcinoma The authors have no other relevant affiliations or financial involvement with any AD32 regulatory t-cells Urinary Bladder Neoplasms n-trifluoroacetyladriamycin-14-valerate ad-32 precision medicine Fdg-pet cells invivo NK lysis Intravesical immunization transduction institutionally directed clinical trial support from Horizon Pharma ER Plimack genetic counselling human papillomavirus programmed death 1
Last updated on Friday, February 02, 2018